Best Practice & Research Clinical Haematology
Volume 19, Issue 2 , Pages 321-328 , June 2006

Are matched unrelated donor transplants justified for AML in CR1?

References 

  1. Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer. 2005;103:1652–1658
  2. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411:385–389
  3. Tallman M, Dewald G, Lazarus HM, et al. Impact of cytogenetics on outcome of unrelated donor hematopoietic stem cell transplantation for adults with AML. Blood. 2004;104:237a;[abstr 830]
  4. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075–4083
  5. Kim DH, Sohn SK, Kim JG, et al. Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation. Annals of Hematology. 2005;84:25–32
  6. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood. 2001;97:56–62
  7. Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. British Journal of Haematology. 2002;118:385–400
  8. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplant outcome. Blood. 2004;104:1923–1930
  9. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89:3055–3060
  10. McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003;101:2043–2048
  11. Bornhauser M, Storer B, Slattery JT, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood. 2003;102:820–826
  12. Radich JP, Gooley T, Bensinger W, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood. 2003;102:31–35
  13. Sobocinski KA, Thall PF, Bekele N, et al. Matched Pairs analysis of IV vs. PO Busulfan as a conditioning agent prior to transplantation. Blood. 2004;104:103a;[abstr 349, Ref Type: Abstract]
  14. de Lima M, Shahjahan M, Alamo A, et al. Allogeneic hematopoietic stem cell transplantation (HSCT) for patients aged 65 years or older with AML and MDS. Blood. 2004;104:632a;[abstr 2301]
  15. Field T, Perkins J, Alsina M, et al. Targeted intravenous busulfan combined with fludarabine (tBuFlu) as conditioning prior to allogeneic peripheral blood stem cell transplant: early results of low treatment related mortality. Blood. 2005;106:500a;[abstr 1759]

PII: S1521-6926(05)00125-8

doi: 10.1016/j.beha.2005.12.002

Best Practice & Research Clinical Haematology
Volume 19, Issue 2 , Pages 321-328 , June 2006

Article Tools

* Image Usage & Resolution